AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Peripheral T-cell Lymphoma (PTCL)
PTCL-NOS
ALCL
AITL

Interventions

DRUG: AZD3470
DRUG: Pembrolizumab

Sponsor

AstraZeneca